trial · primary record
Amivantamab
Carcinoma, Non-Small-Cell Lung
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2029-04-30 |
| Primary endpoint | Phase 1: Number of Participants with Adverse Events (AEs) by Severity |
| Registry ID | NCT07227025 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:57.708Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07227025
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Amivantamab · compound